6367 related articles for article (PubMed ID: 2749491)
1. Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
Osieka R; Glatte P; Schmidt CG
Strahlenther Onkol; 1989 Jul; 165(7):526-8. PubMed ID: 2749491
[No Abstract] [Full Text] [Related]
2. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
Cancer Treat Rep; 1986 Oct; 70(10):1167-71. PubMed ID: 3756939
[TBL] [Abstract][Full Text] [Related]
3. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
[No Abstract] [Full Text] [Related]
4. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
Rose WC; Trader MW; Dykes DJ; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Dec; 62(12):2085-93. PubMed ID: 751716
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
Cohen MH; Schoenfeld D; Wolter J
Cancer Treat Rep; 1980 Jan; 64(1):151-3. PubMed ID: 6991102
[TBL] [Abstract][Full Text] [Related]
6. [Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
Osieka R; Glatte P; Haedecke U; Schmidt CG
Strahlentherapie; 1982 Oct; 158(10):620-9. PubMed ID: 7179344
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy of transplanted rat leukemia L 5222 with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and cyclophosphamide (CPA) as well as with methyl-CCNU and CPA (author's transl)].
Zeller WJ; Berger M
Arzneimittelforschung; 1981; 31(2):303-5. PubMed ID: 7194646
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a new nitrosoureido water-soluble sugar, ecomustine or CY 233 (NSC 609224), on human xenografts.
Dumont P; Atassi G; Roger P
In Vivo; 1990; 4(1):61-4. PubMed ID: 2103843
[TBL] [Abstract][Full Text] [Related]
9. The combination of methyl-CCNU and irradiation: cell survival studies on a human tumor xenograft.
Bateman AE; Fu KK; Towse GD
Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1545-8. PubMed ID: 536260
[No Abstract] [Full Text] [Related]
10. DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenograms in nude mice.
Thomas CB; Osieka R; Kohn KW
Cancer Res; 1978 Aug; 38(8):2448-54. PubMed ID: 667842
[TBL] [Abstract][Full Text] [Related]
11. Nitrosoureas in the management of disseminated malignant melanoma.
Ahmann DL
Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
[No Abstract] [Full Text] [Related]
13. Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
Cancer Chemother Pharmacol; 1983; 11(3):147-52. PubMed ID: 6227420
[TBL] [Abstract][Full Text] [Related]
14. In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
Kirkwood JM; Marsh JC
Cancer Res; 1983 Jul; 43(7):3434-40. PubMed ID: 6850650
[TBL] [Abstract][Full Text] [Related]
15. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
Mulcahy RT; Siemann DW
Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
[TBL] [Abstract][Full Text] [Related]
16. Methyl-CCNU inclinical cancer therapy.
Wasserman TH; Slavik M; Carter SK
Cancer Treat Rev; 1974 Dec; 1(4):251-69. PubMed ID: 4377543
[No Abstract] [Full Text] [Related]
17. Methyl-CCNU for patients with previously treated metastatic neuroblastoma--a phase II study.
Evans AE; Bernstein I; Finklestein J; Klemperer M; Leikin S; Weiner JM; Hammond GD
Cancer Treat Rep; 1977; 61(1):83-5. PubMed ID: 324623
[No Abstract] [Full Text] [Related]
18. Results with methyl-CCNU and DTIC in metastatic melanoma.
Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
[TBL] [Abstract][Full Text] [Related]
19. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Kokoschka EM; Luger T; Micksche M
Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ
Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
